COMPOUND PROFILE / PEPTIDES & ANALOGUES
Cotadutide.
Research draftCotadutide is a dual GLP-1 and glucagon receptor agonist.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Cotadutide is a dual GLP-1 and glucagon receptor agonist.
Mechanism
It combines appetite and glucose-related effects with glucagon-mediated metabolic actions.
Human research
Randomised studies investigated diabetes, weight and liver-disease outcomes; trial results are indication-specific.
Preclinical & other research
Metabolic models explored dual-receptor activity.
Safety & unknowns
Gastrointestinal symptoms and metabolic effects require clinical assessment; sustained benefit is not established for every proposed use.
Regulatory status
Clinical research does not establish marketing approval or justify online products.
Reported use & evidence
The supplied Cotadutide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.